You are here: Home » International » News » Others
Business Standard

Brazil's health regulator allows resumption of China's Covid vaccine trial

Brazil's President Jair Bolsonaro, a longtime China skeptic who has baselessly dismissed the Sinovac vaccine as lacking in credibility, had hailed Monday's suspension as a personal victory

Topics
Brazil | Coronavirus Vaccine | China

Reuters  |  BRASILIA 

Covid-19 coronavirus

BRASILIA (Reuters) - Brazil's health regulator Anvisa announced on Wednesday the resumption of clinical Phase III trials for China's Sinovac COVID-19 vaccine.

Anvisa on Monday suspended the trials of the Sinovac vaccine after the death of a volunteer that was registered as a suicide.

The regulator said that it had not been informed of the cause of the volunteers' death when it took the decision and was only provided with the details the following day by the Butantan biomedical center which is running the trials.

"After evaluating the new data presented by the sponsor... Anvisa understands that it has sufficient reasons to allow the resumption of vaccination," the agency's statement said.

"It is important to clarify that a suspension does not necessarily mean that the product under investigation does not offer quality, safety or efficacy," Anvisa said.

 

 

 

(Reporting by Anthony Boadle; editing by Stephen Eisenhammer)

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Wed, November 11 2020. 22:36 IST
RECOMMENDED FOR YOU
.